scholarly journals COVID-19 AND PATIENTS UNDERGOING PHARMACOLOGICAL TREATMENTS FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES: PROTOCOL FOR A RAPID LIVING SYSTEMATIC REVIEW

2020 ◽  
Author(s):  
Maria Eduarda dos Santos Puga ◽  
Aline Pereira da Rocha ◽  
Alvaro Nagib Atallah ◽  
Ana Carolina Pereira Nunes Pinto ◽  
César Ramos Rocha-Filho ◽  
...  
Keyword(s):  
Systematic Review ◽  
Inflammatory Diseases ◽  
Pharmacological Treatments ◽  
Immune Mediated

scholarly journals COVID-19 AND PATIENTS UNDERGOING PHARMACOLOGICAL TREATMENTS FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES: PROTOCOL FOR A RAPID LIVING SYSTEMATIC REVIEW

2020 ◽  
Author(s):  
Aline Pereira da Rocha ◽  
Alvaro Nagib Atallah ◽  
Ana Carolina Pereira Nunes Pinto ◽  
César Ramos Rocha-Filho ◽  
Felipe Sebastião de Assis Reis ◽  
...  
Keyword(s):  
Systematic Review ◽  
Inflammatory Diseases ◽  
Meta Analysis ◽  
Grey Literature ◽  
Pharmacological Treatments ◽  
Systematic Review Methodology ◽  
Systematic Review Methods ◽  
Immune Mediated ◽  
Synthetic Dmards ◽  
Disease Modifying

ABSTRACTCONTEXT AND OBJECTIVEWe propose to systematically review the available evidence to evaluate if patients with immune mediated inflammatory diseases under pharmacological treatment with immunosuppressants, immunobiologics, Disease-Modifying Anti-Rheumatic Drugs (DMARD) or targeted synthetic DMARDs have better or worse outcomes when infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This study is a protocol for our rapid living systematic review. METHODS: Protocol for a rapid living systematic review methodology following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidance. To conduct the rapid systematic review, we will employ abbreviated systematic review methods, including: not performing independent screens of abstracts and not searching grey literature. As this will be a living review, it will be continuously updated.

scholarly journals COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review

2020 ◽  
Vol 138 (6) ◽  
pp. 515-520
Author(s):  
Aline Pereira da Rocha ◽  
Álvaro Nagib Atallah ◽  
Ana Carolina Pereira Nunes Pinto ◽  
César Ramos Rocha-Filho ◽  
Keilla Martins Milby ◽  
...  
Keyword(s):  
Systematic Review ◽  
Inflammatory Diseases ◽  
Pharmacological Treatments ◽  
Immune Mediated

scholarly journals The influence of biologics on the microbiome in immune-mediated inflammatory diseases: A systematic review

2021 ◽  
Vol 141 ◽  
pp. 111904
Author(s):  
Jakub Ruszkowski ◽  
Agnieszka Daca ◽  
Adrian Szewczyk ◽  
Alicja Dębska-Ślizień ◽  
Jacek M. Witkowski
Keyword(s):  
Systematic Review ◽  
Inflammatory Diseases ◽  
Immune Mediated

scholarly journals Outcome selection for tissue-agnostic drug trials for immune-mediated inflammatory diseases: a systematic review of core outcome sets and regulatory guidance

Trials ◽  
2022 ◽  
Vol 23 (1) ◽  
Author(s):  
Olalekan Lee Aiyegbusi ◽  
Lavinia Ferrante di Ruffano ◽  
Ameeta Retzer ◽  
Philip N. Newsome ◽  
Christopher D. Buckley ◽  
...  
Keyword(s):  
Systematic Review ◽  
Inflammatory Diseases ◽  
Core Outcome ◽  
Core Outcome Sets ◽  
Regulatory Guidance ◽  
Immune Mediated ◽  
Outcome Selection ◽  
Similarities And Differences ◽  
Selection For

Abstract Background Tissue-agnostic drug development provides a paradigm shift in precision medicine and requires innovative trial designs. However, outcome selection for such trials can prove challenging. The objectives of this review were to: Identify and map core outcome sets (COS), across 11 immune-mediated inflammatory diseases (IMIDs) in order to facilitate the selection of relevant outcomes across the conditions for innovative trials of tissue-agnostic drug therapies. Compare outcomes or endpoints recommended by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to identify and highlight similarities and differences. Methods The Core Outcome Measures in Effectiveness Trials (COMET), International Consortium for Health Outcomes Measurement (ICHOM), FDA and EMA databases were searched from inception to 28th December 2019. Two reviewers independently screened titles and abstracts of retrieved entries and conducted the subsequent full text screening. Hand searching of the reference lists and citation searching of the selected publications was conducted. The methodological quality of the included peer-reviewed articles was independently assessed by the reviewers based on the items of the COS–Standards for Development recommendations (COS–STAD) checklist. Core outcomes from the included publications were extracted and mapped across studies and conditions. Regulatory guidance from FDA and EMA, where available for clinical trials for the IMIDs, were obtained from their databases and recommendations on outcomes to measure directly compared. Results Forty-four COS publications were included in the final analysis. Outcomes such as disease activity, pain, fatigue, quality of life, physical function, work limitation/productivity, steroid use and biomarkers were recommended across majority of the conditions. There were significant similarities and differences in FDA and EMA recommendations. The only instance where either regulatory body directly referenced a COS was for jSLE—both referenced the Paediatric Rheumatology International Trials Organization (PRINTO) COS. Conclusions The findings from this systematic review provide valuable information to inform outcome selection in tissue-agnostic trials for IMIDs. There is a need for increased collaboration between regulators and COS developers and inclusion of regulators as key stakeholders in COS development to enhance the quality of COS. Trial registration Not registered.

scholarly journals Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis

2021 ◽  
pp. 102927
Author(s):  
Anuraag Jena ◽  
Shubhra Mishra ◽  
Parakkal Deepak ◽  
Praveen Kumar-M ◽  
Aman Sharma ◽  
...  
Keyword(s):  
Systematic Review ◽  
Inflammatory Diseases ◽  
Meta Analysis ◽  
Immune Mediated

The Role of Th17/Treg Axis in the Traditional Chinese Medicine Intervention on Immune-Mediated Inflammatory Diseases: A Systematic Review

2020 ◽  
Vol 48 (03) ◽  
pp. 535-558
Author(s):  
Yong-Yue Xu ◽  
Dong-Mei Wang ◽  
Hua-Sheng Liang ◽  
Ze-Hao Liu ◽  
Jun-Xia Li ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Frequency Analysis ◽  
Inflammatory Diseases ◽  
Receptor Type ◽  
Network Pharmacology ◽  
Tgf Beta ◽  
Immune Mediated ◽  
Regulatory Effects

The Th17/Treg axis plays a crucial role in immune-mediated inflammatory diseases (IMID) and might represent an interesting drug target of treatment strategy for these diseases. Accumulating evidence suggests a role for traditional Chinese medicine (TCM) in the modulation of Th17/Treg axis, but a comprehensive overview which summarizes this field hitherto is lacked. This paper performs a systematic literature review of the regulatory effects of TCM on the imbalance of Th17/Treg axis and its potential mechanisms. In addition, the frequency analysis and network pharmacology for the collected TCM herbs from clinical trial data were performed. The studies reported the changes in the ratio of Th17 and/or Treg cells as well as their transcription factor and related cytokines were included. Frequency analysis of composition of the 39 assessed TCM prescriptions showed that Astragalus membranaceus var.mongholicus (5.20%), Glycyrrhiza uralensis (3.67%), Paeonia obovate (3.06%), Salvia digitaloides (3.06%), and Angelica sinensis (2.75%) were the top five herbal components, which were closely associated to the treatment of IMID. Network pharmacology showed that six target proteins (transforming growth factor (TGF)-beta receptor type-1, TGF-beta receptor type-2, retineic-acid-receptor-related orphan nuclear receptor gamma (ROR-gamma), TGFB2, IL-17 and IL-2, respectively) might be involved in the regulatory effects of TCM on Th17/Treg axis. Moreover, there were nine active ingredients (including Oxymatrine, Baicalin, Triptolide, Paeoniflorin, Sinomenine, Celastrol, Emodin, Diosgenin and Chlorogenic acid) originating from TCM reported to have an immunological regulation effect on the Th17/Treg axis. The highlight of this systematic review is to reveal the pharmacological basis of TCM treating IMID and is helpful for supporting future pharmacologic-driven studies. Further research elucidates the immune-modulating mechanisms on Th17/Treg axis by TCM might provide a broader insight for the treatment of IMID.

Pre-Morbid Obesity is Associated with Increased Risk of Developing Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis

2017 ◽  
Vol 152 (5) ◽  
pp. S976-S977 ◽  
Author(s):  
Siddharth Singh ◽  
Mathurin Fumery ◽  
Katherine Shaffer ◽  
Abha G. Singh ◽  
Larry Prokop ◽  
...  
Keyword(s):  
Systematic Review ◽  
Morbid Obesity ◽  
Inflammatory Diseases ◽  
Meta Analysis ◽  
Immune Mediated ◽  
Increased Risk
Sign in / Sign up

Export Citation Format

Share Document